Interferon and natural killer cells in systemic lupus erythematosus - PubMed (original) (raw)

PMID: 6185256
PMCID: PMC1536671

Interferon and natural killer cells in systemic lupus erythematosus

O Strannegård et al. Clin Exp Immunol. 1982 Nov.

Abstract

Natural killer (NK) cell activity against several types of target cells was found to be subnormal in patients with systemic lupus erythematosus (SLE). Interferon (IFN) boosted the NK activity of cells from SLE patients to a significantly lesser degree than cells from normal controls. The production of IFN after stimulation of blood cells with Sendai virus was significantly decreased in SLE patients with active disease, and in a substantial proportion of the patients the production of phytohaemagglutinin (PHA)-induced IFN was below normal limits. Although the production of virus-induced IFN was clearly inversely correlated to disease activity no such correlation was observed for PHA-induced IFN. Serum levels of both pH2 stable and pH2 labile IFN were significantly higher in SLE patients than in controls. The findings clearly show that SLE is associated with abnormalities in the NK cell-IFN system but it cannot be stated whether these abnormalities are causally related to the development of disease or are secondary to pathological changes in SLE.

PubMed Disclaimer

Cited by

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.
Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Vallin H, et al. Clin Exp Immunol. 1999 Jan;115(1):196-202. doi: 10.1046/j.1365-2249.1999.00772.x. Clin Exp Immunol. 1999. PMID: 9933442 Free PMC article.
Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.
Struyf NJ, Snoeck HW, Bridts CH, De Clerck LS, Stevens WJ. Struyf NJ, et al. Ann Rheum Dis. 1990 Sep;49(9):690-3. doi: 10.1136/ard.49.9.690. Ann Rheum Dis. 1990. PMID: 1700674 Free PMC article.
BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction.
Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Günther G, Johnston I, Lanzavecchia A, Nagasaka T, Okada T, Vermi W, Winkels G, Yamamoto T, Zysk M, Yamaguchi Y, Schmitz J. Dzionek A, et al. J Exp Med. 2001 Dec 17;194(12):1823-34. doi: 10.1084/jem.194.12.1823. J Exp Med. 2001. PMID: 11748283 Free PMC article.
Serum levels of interferons in patients with systemic lupus erythematosus.
Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Kim T, et al. Clin Exp Immunol. 1987 Dec;70(3):562-9. Clin Exp Immunol. 1987. PMID: 2449306 Free PMC article.
Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.
Pedersen BK, Oxholm P, Manthorpe R, Andersen V. Pedersen BK, et al. Clin Exp Immunol. 1986 Jan;63(1):1-7. Clin Exp Immunol. 1986. PMID: 3485480 Free PMC article.

References

1. J Clin Invest. 1973 Dec;52(12):3046-56 - PubMed
1. Arthritis Rheum. 1974 Sep-Oct;17(5):590-2 - PubMed
1. Arthritis Rheum. 1975 May-Jun;18(3):207-17 - PubMed
1. Scand J Immunol. 1975;4(2):145-50 - PubMed
1. Clin Immunol Immunopathol. 1976 Sep;6(2):192-9 - PubMed

Interferon and natural killer cells in systemic lupus erythematosus - PubMed (original) (raw)